These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

384 related items for PubMed ID: 10194088

  • 1. Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients.
    Nguyen Q, Champlin R, Giralt S, Rolston K, Raad I, Jacobson K, Ippoliti C, Hecht D, Tarrand J, Luna M, Whimbey E.
    Clin Infect Dis; 1999 Mar; 28(3):618-23. PubMed ID: 10194088
    [Abstract] [Full Text] [Related]

  • 2. Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients.
    Canpolat C, Culbert S, Gardner M, Whimbey E, Tarrand J, Chan KW.
    Bone Marrow Transplant; 1996 Apr; 17(4):589-93. PubMed ID: 8722360
    [Abstract] [Full Text] [Related]

  • 3. Cytomegalovirus surveillance and prevention in allogeneic bone marrow transplantation: examination of a preemptive plan of ganciclovir therapy.
    Mandanas RA, Saez RA, Selby GB, Confer DL.
    Am J Hematol; 1996 Feb; 51(2):104-11. PubMed ID: 8579049
    [Abstract] [Full Text] [Related]

  • 4. Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir.
    Ippoliti C, Morgan A, Warkentin D, van Besien K, Mehra R, Khouri I, Giralt S, Gajewski J, Champlin R, Andersson B, Przepiorka D.
    Bone Marrow Transplant; 1997 Sep; 20(6):491-5. PubMed ID: 9313883
    [Abstract] [Full Text] [Related]

  • 5. Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation.
    Stocchi R, Ward KN, Fanin R, Baccarani M, Apperley JF.
    Haematologica; 1999 Jan; 84(1):71-9. PubMed ID: 10091394
    [Abstract] [Full Text] [Related]

  • 6. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation.
    Burns LJ, Miller W, Kandaswamy C, DeFor TE, MacMillan ML, Van Burik JA, Weisdorf DJ.
    Bone Marrow Transplant; 2002 Dec; 30(12):945-51. PubMed ID: 12476289
    [Abstract] [Full Text] [Related]

  • 7. A randomised trial comparing cytomegalovirus antigenemia assay vs screening bronchoscopy for the early detection and prevention of disease in allogeneic bone marrow and peripheral blood stem cell transplant recipients.
    Humar A, Lipton J, Welsh S, Moussa G, Messner H, Mazzulli T.
    Bone Marrow Transplant; 2001 Sep; 28(5):485-90. PubMed ID: 11593322
    [Abstract] [Full Text] [Related]

  • 8. Cytomegalovirus pneumonia in adult autologous blood and marrow transplant recipients.
    Konoplev S, Champlin RE, Giralt S, Ueno NT, Khouri I, Raad I, Rolston K, Jacobson K, Tarrand J, Luna M, Nguyen Q, Whimbey E.
    Bone Marrow Transplant; 2001 Apr; 27(8):877-81. PubMed ID: 11477447
    [Abstract] [Full Text] [Related]

  • 9. CMV monitoring after peripheral blood stem cell and bone marrow transplantation by pp65 antigen and quantitative PCR.
    Schulenburg A, Watkins-Riedel T, Greinix HT, Rabitsch W, Loidolt H, Keil F, Mitterbauer M, Kalhs P.
    Bone Marrow Transplant; 2001 Oct; 28(8):765-8. PubMed ID: 11781628
    [Abstract] [Full Text] [Related]

  • 10. Forscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study.
    Moretti S, Zikos P, Van Lint MT, Tedone E, Occhini D, Gualandi F, Lamparelli T, Mordini N, Berisso G, Bregante S, Bruno B, Bacigalupo A.
    Bone Marrow Transplant; 1998 Jul; 22(2):175-80. PubMed ID: 9707026
    [Abstract] [Full Text] [Related]

  • 11. Prophylactic ganciclovir is more effective in HLA-identical family member marrow transplant recipients than in more heavily immune-suppressed HLA-identical unrelated donor marrow transplant recipients. Australasian Bone Marrow Transplant Study Group.
    Atkinson K, Arthur C, Bradstock K, Dale B, Downs K, Gibson J, Golenia M, Ho J, Joshua D, Juttner C.
    Bone Marrow Transplant; 1995 Sep; 16(3):401-5. PubMed ID: 8535313
    [Abstract] [Full Text] [Related]

  • 12. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients.
    Shereck EB, Cooney E, van de Ven C, Della-Lotta P, Cairo MS.
    Pediatr Blood Cancer; 2007 Sep; 49(3):306-12. PubMed ID: 16972242
    [Abstract] [Full Text] [Related]

  • 13. Extended routine polymerase chain reaction surveillance and pre-emptive antiviral therapy for cytomegalovirus after allogeneic transplantation.
    Peggs KS, Preiser W, Kottaridis PD, McKeag N, Brink NS, Tedder RS, Goldstone AH, Linch DC, Mackinnon S.
    Br J Haematol; 2000 Dec; 111(3):782-90. PubMed ID: 11122138
    [Abstract] [Full Text] [Related]

  • 14. Cytomegalovirus as a cause of very late interstitial pneumonia after bone marrow transplantation.
    de Medeiros CR, Moreira VA, Pasquini R.
    Bone Marrow Transplant; 2000 Aug; 26(4):443-4. PubMed ID: 10982292
    [Abstract] [Full Text] [Related]

  • 15. Early treatment of CMV infections in allogeneic bone marrow transplant recipients with foscarnet or ganciclovir.
    Bacigalupo A, van Lint MT, Tedone E, Moro F, Sanna MA, Longren M, Trespi G, Frassoni F, Occhini D, Gualandi F.
    Bone Marrow Transplant; 1994 Jun; 13(6):753-8. PubMed ID: 7920310
    [Abstract] [Full Text] [Related]

  • 16. Cytomegalovirus disease in adult marrow transplant recipients receiving ganciclovir prophylaxis: a retrospective study.
    Maltezou H, Whimbey E, Abi-Said D, Przepiorka D, Champlin R, Goodrich J.
    Bone Marrow Transplant; 1999 Sep; 24(6):665-9. PubMed ID: 10490734
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.